Carmichael Hill & Associates’s Fulgent Genetics FLGT Stock Holding History
Bought
Maintained
Sold
Other funds holding FLGT
PWAM
DSCM
Carmichael Hill & Associates's FLGT Position: Q1 2022 in Review
Carmichael Hill & Associates sold out of Fulgent Genetics (FLGT) in Q1 2022, closing a stake of 500 shares — an estimated $32.9K sold.
Carmichael Hill & Associates first reported a position in FLGT in Q1 2021 and held it in 4 quarters. The position peaked at $50K in Q4 2021. 275 funds tracked by Wall St. Rank hold FLGT as of Q1 2022.
- Carmichael Hill & Associates reported no remaining Fulgent Genetics position as of Q1 2022 after selling out during the quarter.
- Carmichael Hill & Associates sold 500 Fulgent Genetics shares in Q1 2022, an estimated $32.9K.
- Carmichael Hill & Associates first reported a position in Fulgent Genetics in Q1 2021 and held it in 4 quarters.
- Carmichael Hill & Associates's Fulgent Genetics position peaked at $50K in Q4 2021.
- 275 funds tracked by Wall St. Rank held Fulgent Genetics as of Q1 2022.
Based on Carmichael Hill & Associates's 13F filing for Q1 2022, filed 16 May 2022.